Associate Scientist II, Technical Development
Posted on: 18 Jan 2021
Research Triangle Park, NC
Job Description
Job Description
The successful candidate will join Analytical Development at Biogen, focusing on testing support and assay development for protein bioassay and gene therapy programs.
Responsibilities:
The individual will develop and perform quantitative assays to measure relative binding and relative potency of protein and gene therapy products, as well as assays measuring the levels of residual host DNA, protein, and other process-related impurities.
Responsibilities include data analysis, recording keeping, report writing and reviewing, and internal technical presentations.
Qualifications
* Solid background in molecular and cell biology.
* Previous experience with bioassays in 96-well format and multichannel pipetting is required.
* Mammalian cell culture, qPCR and/or ddPCR, and automation experience preferred. Previous work with AAV or lentivirus is a plus.
* The ideal candidate is a fast learner with strong scientific curiosity, good interpersonal skills, and attention to detail. In addition, the candidate should have excellent laboratory, computer, documentation, and organizational skills, as well as good communication abilities who enjoys working independently in a fast-paced environment with changing priorities.
Education:
B.S with 0-2 years of experience in Biochemistry, Biology, or related Biological Sciences.
Additional Information
All your information will be kept confidential according to EEO guidelines.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
